ClinicalTrials.gg
RecruitingNCT06358040Updated Dec 8, 2025

Opioid Dispenser for Microdiscectomy/Laminectomy

An interventional study of Opioid-Dispensing Device and App in Opioid Use, Pain, Postoperative and Medical Device, sponsored by Hospital for Special Surgery, New York. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Hospital for Special Surgery, New York · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Pain, Postoperative by Hospital for Special Surgery, New York — 2 open to participants now, 2 under way, 1 of them phase 3. Pain, Postoperative · Hospital for Special Surgery, New York.

Planned enrollment
11th of 14
30 · median 44
Started
2026
the only one that year
No phase
8 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Pain, Postoperative by Hospital for Special Surgery, New York, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 8 with no phase, and was the 17th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 17 studies in Pain, Postoperative by Hospital for Special Surgery, New York are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pain, Postoperative by Hospital for Special Surgery, New York, or all of them as a file.
02

Study summary

The opioid crisis continues to plague the United States. While great strides have been made nationwide to decrease overprescribing, improvements are still needed to appropriately educate patients on the safe and responsible use, storage and disposal of opioids. Pain after surgery is often treated with opioid medications. Opioid medications can have side effects. Some side effects are relatively minor (constipation, nausea, vomiting), while others are more severe (sedation, abnormal breathing, etc.) and can lead to serious illness or death. Opioid pain medications when used the wrong way may also be addictive. Due to theses side effects, sometimes patients feel uncomfortable about taking these medications, and doctors prescribe them very cautiously. However, when used properly and safely, opioid pain medications are excellent pain relievers.

Addinex, a technology company, has developed a device to help patients take opioids more safely. In this study the investigators aim to enroll a total of 30 patients who undergo spine surgery. Half will be randomly assigned to receive a standard pill bottle with opioids at discharge and will download a mobile app so that they can record their daily pain scores and the number of opioids they take for two weeks after surgery. The other half will receive the new opioid dispenser filled with opioids and a mobile app that generates a passcode that opens that device only at designated times. For this group of patients, every time the patient wants to take an opioid, they need to go to the app, enter their pain score before the app generates a passcode. The investigators will be tracking all study patients' opioid use and pain scores for the two weeks after surgery, will count how many pills they have left over 14 days after their surgery during a live telehealth session, and ask patients how they liked using the device. Results from this study will help understand if the Addinex device could potentially be useful to patients in the future after surgeries as opposed to typical pill bottles.

03

Conditions studied

  • Opioid Use
  • Pain, Postoperative
  • Medical Device
  • Laminectomy
  • Diskectomy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • opioid-naive patients or intermittent opioid users within 3 months of scheduled surgery
  • At least 18 years old
  • presenting for primary elective one-level lumbar laminectomy and/or discectomy via posterior approach with participating surgeon
  • planned discharge on day of surgery/23 hour admission
  • planned discharge to home

Exclusion criteria

Exclusion Criteria:

  • patients with opioid-tolerance
  • patients without a smart-phone or without the ability to perform Telehealth visits
  • patients unable to utilize the medication dispensing device
  • patients presenting for other surgeries/surgeries with combined anterior/lateral approaches
  • patient refusal
  • allergy or intolerance to opioids
  • planned admission after surgery
  • planned discharge disposition to nursing facility or skilled rehabilitation
  • planned use of or preference for opioid other than oxycodone
  • patients who are pregnant
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Standard Opioid Pill Bottle with App

    Other: App · Other: Standard Opioid Pill Bottle

  • Experimental
    Opioid-Dispensing Device with App

    Device: Opioid-Dispensing Device · Other: App

Interventions

  • DeviceOpioid-Dispensing Device

    Addinex Opioid-Dispensing Device

    Also known as: Addinex

  • OtherApp

    Addinex App

    Also known as: Addinex

  • OtherStandard Opioid Pill Bottle

    Standard Opioid Pill Bottle

06

What researchers measure

Primary outcomes

  1. Cumulative Opioid Consumption at Postoperative Day 14 (POD14)

    Cumulative Opioid Consumption at Postoperative Day 14 (POD14) following lumbar decompression (microdiscectomy/laminectomy), expressed as number of tablets and morphine equivalents (MED in mg) and collected via app starting at discharge to 14 days later.

    Time frame: Hospital Discharge to Postoperative Day 14

Secondary outcomes

  1. NRS pain intensity ratings

    Numerical Rating Scale (NRS) Pain Intensity Ratings from 0-10, with 0 being no pain to 10 being the worst pain possible: patient-reported in app

    Time frame: PACU; Daily after Hospital Discharge: Postoperative Day 1 up to Postoperative Day 14

  2. Patient satisfaction with the app and with the dispensing device

    Satisfaction survey - Device group patients will rate statements on a 5-point scale, from 1 (strongly disagree) to 5 (strongly agree)

    Time frame: Postoperative Day 14

  3. Frequency of reported difficulties using the device

    Frequency of reported difficulties using the device assessed via initiation of patient call to study team; activation of device unlocking mechanism.

    Time frame: Daily up to Postoperative Day 14

  4. Frequency of reported difficulties using the app

    Frequency of reported difficulties using the app assessed via initiation of patient call/email to study team.

    Time frame: Daily up to Postoperative Day 14

  5. Opioid prescription refill rates

    Opioid prescription refill rates using electronic health records

    Time frame: 6 weeks postoperatively

  6. Concordance of app data and medication left in the device or pill bottle (medication reconciliation)

    At Postoperative Day 14, the number of pills consumed as documented via the app, compared to actual pills left over in the device/pill bottle (telemedicine medication reconciliation).

    Time frame: Postoperative Day 14

  7. Generation of one-time use over-ride code

    Device group: Generation of one-time use over-ride code to dispense one opioid tablet, assessed via email to study team

    Time frame: Daily up to Postoperative Day 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication

Access criteria: For researchers who provide a methodologically sound proposal and analyses to achieve aims in the approved proposal. Proposals should be directed to siderisa@hss.edu. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 0 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2024
First posted
Apr 10, 2024
StartEst.
Oct 2026
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06358040
Responsible party
Sponsor
First posted
Apr 10, 2024
Start date
Oct 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 8, 2025

Study contacts

William Chan, MEng
Contact
chanw@hss.edu
917-260-4788
Alexandra Sideris, PhD
Contact
siderisa@hss.edu
212-774-2602
Vladimir Kramskiy, MD
principal investigator · Hospital for Special Surgery, New York

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion